{"id":"torasemide-pr","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Ototoxicity (at high doses)"},{"rate":null,"effect":"Dehydration"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL3314608","moleculeType":"Small molecule","molecularWeight":"691.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Torasemide blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This leads to increased urine output and reduced blood volume and pressure. The PR (prolonged-release) formulation extends the drug's duration of action through modified-release technology.","oneSentence":"Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:13:20.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Edema associated with congestive heart failure"},{"name":"Edema associated with hepatic cirrhosis"},{"name":"Edema associated with renal disease"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT00334386","phase":"PHASE4","title":"Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2005-04","conditions":"Hypertension","enrollment":388},{"nctId":"NCT01549158","phase":"PHASE4","title":"Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure","status":"TERMINATED","sponsor":"Ferrer Internacional S.A.","startDate":"2012-02","conditions":"Compensated Heart Failure","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"torasemide-PR","genericName":"torasemide-PR","companyName":"Ferrer Internacional S.A.","companyId":"ferrer-internacional-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Torasemide is a loop diuretic that inhibits sodium and chloride reabsorption in the ascending limb of the loop of Henle, promoting urinary excretion of water and electrolytes. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}